TITLE

Diabetic Peripheral Neuropathic Pain: Case Studies

AUTHOR(S)
Belgrade, Miles J.; Cole, B. Eliot; McCarberg, Bill H.; McLean, Michael J.
PUB. DATE
April 2006
SOURCE
Mayo Clinic Proceedings;Apr2006 Supplement, Vol. 81 Issue 4, pS26
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Three case reports in this article illustrate the diagnostic methods used and the treatment course encountered for many patients with diabetic peripheral neuropathic pain (DPNP). Each case addresses an aspect of DPNP: pain that appears to be refractory to initial therapy, DPNP occurring with other medical conditions, and nondiabetic neuropathy occurring in patients with diabetes mellitus. Together, these cases bring clarity to the confusing clinical experience for patients who have decreased sensation in combination with burning pain, and they apply the consensus guidelines for DPNP. Recently approved medications by the Food and Drug Administration for the treatment of DPNP offer hope for many patients whose pain was thought to be refractory to treatment.
ACCESSION #
20475302

 

Related Articles

  • New insulin helps control blood glucose levels. Hitchens, Kathy // Drug Topics;7/25/2005, Vol. 149 Issue 14, p10 

    This article reports that approval of insulin detemir by the U.S. Food and Drug Administration. The approval rounds out the Novo Nordick product line for diabetes. It also adds a new tool to help patients with diabetes achieve blood glucose targets and perhaps avoid gaining weight. According to...

  • New study finds dysglycemia risk. Elliott, William T. // Infectious Disease Alert;Oct2013 Pharmacology Watch, p1 

    The article reports on a study from Taiwan which found new side effects of the antibiotic fluoroquinolones from 78,000 diabetic patients who were monitored for dysglycemia. It states that hyperglycemia risk per 1,000 patients was 6.9% for those using moxifloxacin and 1.6% for macrolides while...

  • More Side Effects of Fluoroquinolones Coming to Light. Elliott, William T. // Infectious Disease Alert;Oct2013 Pharmacology Watch, p1 

    The article reports on the warning of the U.S. Food and Drug Administration's Drug Safety Communication that the antibiotic fluoroquinolones such as ciprofloxacin, moxifloxacin, and levofloxacin may produce the risk of permanent neuropathy and as such has warned on the parenteral and oral forms...

  • New drugs for lung disease, diabetic pain.  // Consumer Reports on Health;Dec2004, Vol. 16 Issue 12, p10 

    The article reports that two new medications could significantly improve the treatment of people with diabetes or chronic obstructive pulmonary disease, the most prevalent type of lung disease. Duloxetine (Cymbalta) is the first drug approved by the U.S. Food and Drug Administration to treat...

  • Pregabalin has sustained efficacy in neuropathic pain relief.  // Geriatrics;Sep2004, Vol. 59 Issue 9, p37 

    The efficacy of pregabalin in relieving neuropathic pain associated with diabetes or shingles extends to as long as one year, physician Russell Portenoy reported. The agent, pregabalin, is under review by the U.S. Food and Drug Administration for the treatment of neuropathic pain associated with...

  • Pregabalin: An antiepileptic agent useful for neuropathic pain. BLOMMEL, MATTHEW L.; BLOMMEL, AMY L. // American Journal of Health-System Pharmacy;7/15/2007, Vol. 64 Issue 14, p1475 

    Purpose. The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of pregabalin are reviewed. Summary. Pregabalin is the first drug to receive approved labeling from the Food and Drug Administration (FDA) for the treatment of painful diabetic...

  • FDA Actions.  // Travel Medicine Advisor;Aug2007, Vol. 17 Issue 8, p2 

    The article reports on the strict regulation of the U.S. Food and Drug Administration (FDA) on its manufacturing practices for dietary supplements. It also states that these supplements are produced in a quality manner, do not contain impurities and are accurately labeled. Pregabalin from...

  • AVANIR INITIATES PHASE III CLINICAL TRIAL OF NEURODEX.  // Biotech Business;Aug2005, Vol. 18 Issue 8, p5 

    Reports on a clinical trial initiated by pharmaceutical firm Avanir Pharmaceuticals for the drug Neurodex in patients with diabetic neuropathic pain in 2005. Process used by the U.S. Food and Drug Administration to review the clinical trial protocol; Results of the previous trial; Background on...

  • More Side Effects of Fluoroquinolones Coming to Light.  // Internal Medicine Alert;9/15/2013 Pharmacology Watch, p1 

    The article discusses side effects of fluoroquinolones which include antibiotic-related diarrhea, and prostate cancer risk and the U.S. Food and Drug Administration's (FDA;s) actions on this.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics